- Rating
- 1
- Confidence
- 3
- Informativeness
- 1
- Presentation
- 2
- Soundness
- 2
Read review
Paper summary
This paper studies protein-expression prediction from spatial RNA measurements, using a source section with paired RNA and protein data to predict the same protein panel in a target section. BSPP combines an RNA encoder with pretrained UCE features through a learned gate, then predicts a protein latent representation that is decoded by a frozen VAE. The authors evaluate the method on four datasets covering replicate, cross-section, and within-section regional prediction, and report improvements over several RNA-to-protein prediction methods.
Critical strengths
-
The problem is relevant and useful. Joint RNA and protein measurements are not always available, so transferring protein information from a paired reference to an RNA-only target has practical value.
-
Combining RNA features with a pretrained cell representation is a reasonable approach. Predicting through a protein latent space could also help capture relationships among the measured proteins.
-
The evaluation covers several tissues and prediction settings, with both non-spatial and spatial baselines. I also appreciate the stated separation between source-side checkpoint selection and target-protein evaluation.
Critical weaknesses
-
I could not work out whether spatial routing is actually part of the evaluated model. The abstract describes benefit-aware spatial residual routing, but Sections 3.2 and 3.6 explicitly state that only the intrinsic pathway is used and the spatial gate is fixed to zero. Table 2 nevertheless reports changes after removing spatial context. These descriptions need to be reconciled, since they concern a central part of the claimed contribution.
-
Some results are inconsistent across tables. For Human Lymphnode 1→2, BSPP has a protein-wise PCC of 0.354 in Table 1, while “BSPP (full)” has 0.5542 in Table 2. The reverse direction also differs substantially, at 0.350 versus 0.5457. If these are different model configurations or evaluation protocols, this needs to be clearly explained. In the current presentation, it is difficult to interpret the benchmark and ablation results together.
-
The pretraining procedure for the frozen components is not clear enough. The protein VAE and UCE projection are fixed during predictor training, but this does not explain how they were obtained or which samples were used. Since the paper emphasizes a strictly target-blind setting, the data access for these earlier stages needs to be explained as well.
Questions for authors
-
Which exact model produced Table 1 and Table 2? If spatial routing is disabled, why does changing the spatial graph affect predictions?
-
Could you explain the differences between the main benchmark and full-model ablation results, especially on Human Lymphnode? Are the data splits, preprocessing, checkpoints, and scoring procedures identical?
-
How were the protein VAE and frozen UCE projection trained or initialized? Did any stage use target-section protein measurements, including pretraining and preprocessing?